Fundraising FoxArsenal Bridge Venture — Full Portfolio
2 tracked investments · listed companies and verified rows first
Courage Therapeutics is a neuroendocrine biotech developing MC4R agonist drugs for genetic obesity; its lead candidate CTX-B is a weekly injectable targeting melanocortin-4 receptor haploinsufficiency (MC4R HI), a form of early-onset severe obesity with no approved targeted therapy.
BiotechHealthtechLongevityNewton, US
Roger Cone(Co-Founder & CSO)Dan Housman(Co-Founder)Giovanni Ferrara(CEO)Tomi Sawyer(Chief Medicinal Chemist)Sasha Blaug(CBO-CFO)George Grass(Head of Non-Clinical)
Board seatIsaac Barchas· per SEC Form D · $10.5M raise · filed May 2025
Co-investorsAugment Ventures
HealthtechWest Lafayette, US
Philip Low, Ph.D.(Director)Sunil Singhal, M.D.(Director)Isaac Barchas(Director)Clay B. Siegall, Ph.D.(Executive Officer, Director)Ronald Martell(Director)inFranklyn Prendergast, M.D., Ph.D.(Director)
Board seatIsaac Barchas· per SEC Form D · $15M raise · filed May 2023
Co-investorsEcoR1 CapitalJanus Henderson InvestorsREDMILE
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.